Biogen Inc. plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases.
An advisory panel to the U.S. Food and Drug Administration backed an approval for Acadia Pharmaceuticals Inc’s drug for psychosis related to Parkinson’s disease. Nuplazid’s benefits outweighed the risks, the panel said, after 12 members voted in favor of the treatment and two against. Acadia’s shares, which were halted for trading during market hours on […]
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
U.S. health regulators said on Monday that there was no evidence of increased cardiovascular risks related to Novartis AG’s treatment, Stalevo, for Parkinson’s disease. Recommendations for using the drug, which won U.S. approval in 2003, will remain the same on the labels, the U.S. Food and Drug Administration said, after examining data from a required […]
Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. The therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans. Its success is a key step toward proving that embryonic […]